Modeling the therapeutic efficacy of p53 restoration in tumors - PubMed (original) (raw)
. 2006 Dec 29;127(7):1323-34.
doi: 10.1016/j.cell.2006.12.007. Epub 2006 Dec 21.
Affiliations
- PMID: 17182091
- DOI: 10.1016/j.cell.2006.12.007
Free article
Modeling the therapeutic efficacy of p53 restoration in tumors
Carla P Martins et al. Cell. 2006.
Free article
Abstract
Although restoration of p53 function is an attractive tumor-specific therapeutic strategy, it remains unclear whether p53 loss is required only for transition through early bottlenecks in tumorigenesis or also for maintenance of established tumors. To explore the efficacy of p53 reinstatement as a tumor therapy, we used a reversibly switchable p53 knockin (KI) mouse model that permits modulation of p53 status from wild-type to knockout, at will. Using the well-characterized Emu-myc lymphoma model, we show that p53 is spontaneously activated when restored in established Emu-myc lymphomas in vivo, triggering rapid apoptosis and conferring a significant increase in survival. Nonetheless, reimposition of p53 function potently selects for emergence of p53-resistant tumors through inactivation of p19(ARF) or p53. Our study provides important insights into the nature and timing of p53-activating signals in established tumors and how resistance to p53 evolves, which will aid in the optimization of p53-based tumor therapies.
Comment in
- Wild-type p53: tumors can't stand it.
Kastan MB. Kastan MB. Cell. 2007 Mar 9;128(5):837-40. doi: 10.1016/j.cell.2007.02.022. Cell. 2007. PMID: 17350571 Review.
Similar articles
- MIF loss impairs Myc-induced lymphomagenesis.
Talos F, Mena P, Fingerle-Rowson G, Moll U, Petrenko O. Talos F, et al. Cell Death Differ. 2005 Oct;12(10):1319-28. doi: 10.1038/sj.cdd.4401653. Cell Death Differ. 2005. PMID: 15947793 - Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
Baxter EW, Blyth K, Cameron ER, Neil JC. Baxter EW, et al. J Virol. 2001 Oct;75(20):9790-8. doi: 10.1128/JVI.75.20.9790-9798.2001. J Virol. 2001. PMID: 11559812 Free PMC article. - From tumor prevention to therapy: empowering p53 to fight back.
Frezza C, Martins CP. Frezza C, et al. Drug Resist Updat. 2012 Oct;15(5-6):258-67. doi: 10.1016/j.drup.2012.10.001. Epub 2012 Nov 17. Drug Resist Updat. 2012. PMID: 23164556 Review. - In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies.
Simeonova I, Huillard E. Simeonova I, et al. Cell Mol Life Sci. 2014 Oct;71(20):4007-26. doi: 10.1007/s00018-014-1675-3. Epub 2014 Jul 10. Cell Mol Life Sci. 2014. PMID: 25008045 Free PMC article. Review.
Cited by
- RNF2/Ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development.
Su WJ, Fang JS, Cheng F, Liu C, Zhou F, Zhang J. Su WJ, et al. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1720-5. doi: 10.1073/pnas.1211604110. Epub 2013 Jan 14. Proc Natl Acad Sci U S A. 2013. PMID: 23319651 Free PMC article. - The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer.
Otto N, Schulz P, Scholz A, Hauff P, Schlegelberger B, Detjen KM, Wiedenmann B. Otto N, et al. Br J Cancer. 2012 Jan 17;106(2):348-57. doi: 10.1038/bjc.2011.521. Epub 2011 Dec 6. Br J Cancer. 2012. PMID: 22146521 Free PMC article. - Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo.
Kamat CD, Shmueli RB, Connis N, Rudin CM, Green JJ, Hann CL. Kamat CD, et al. Mol Cancer Ther. 2013 Apr;12(4):405-15. doi: 10.1158/1535-7163.MCT-12-0956. Epub 2013 Jan 30. Mol Cancer Ther. 2013. PMID: 23364678 Free PMC article. - Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response.
Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q, Tang X, Pathak S, Raso MG, Burks JK, Lin SY, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Zhao M, et al. Nat Commun. 2024 Jan 2;15(1):180. doi: 10.1038/s41467-023-44239-2. Nat Commun. 2024. PMID: 38167338 Free PMC article. - Hypothermia Effectively Treats Tumors with Temperature-Sensitive p53 Mutations.
Lu J, Chen L, Song Z, Das M, Chen J. Lu J, et al. Cancer Res. 2021 Jul 15;81(14):3905-3915. doi: 10.1158/0008-5472.CAN-21-0033. Epub 2021 Mar 9. Cancer Res. 2021. PMID: 33687951 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous